Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: Dkbunts who wrote (56133)	5/3/2020 12:44:05 PM
From: idahoranch1	10 Recommendations Recommended By alwayshope bnutman bobbseytwins2001 EMU2 jhcimmu and 5 more members Respond to of 63276

Since you are sitting this one out, add this board to that as well.

To: Dkbunts who wrote (56133)	5/3/2020 1:01:48 PM
From: Grass Valley	4 Recommendations Recommended By bnutman bobbseytwins2001 idahoranch1 summer_sky Respond to of 63276

The IMMU therapy is well tolerated with fewer side effects than other treatments. It will probably be used in combination with other other drugs. Look at aids. It used to be a death sentence. Now they have combinations of drugs that allow patients to have an almost normal life. With any luck, we may eventually get to the same place with cancer therapy.

To: Dkbunts who wrote (56133)	5/3/2020 2:24:31 PM
From: TinfoilHat	8 Recommendations Recommended By bobbseytwins2001 EMU2 erippetoe idahoranch1 jargonweary and 3 more members Read Replies (3) \| Respond to of 63276

I don't usually chase down leads posted on this board for other companies, but this one is just too juicy to not pursue further. Look for another post from me in a bit as I parse through the fog, the brutally intense fog that is CyDy aka CytoDyn. And here I was annoyed that Bez was not pumping press releases often enough of ongoing clinical trial results, the CyDy CEO is ejaculating press releases every day! With 7M dollars in the bank vs 1B, wonder which company we should place our bets on, and guess which is which. Good on you for the laugh and for lending this nugget, here I was bored by the quarantine and am now laughing out loud as I dissect this company. Granted, CCR5 is a legit target in HIV, and has immune dampening properties. This has been known for over a decade as Pfizer launched a CCR5 antagonist for HIV called Selzentry many years ago, and the side effect profile was impressive, especially for mitigating cancer long-term and the thought was it was due to Selzentry's immune dampening properties. But to reverse the order and say that drug now cures TNBC, is laughable. Stay tuned, and definitely don't go selling IMMU for CYDN unless you are also willing to wager that Jesus visited the Americas posthumously after his ascension into heaven. Accompanied by angels, no less.